Jacobs Levy Equity Management Inc. Boosts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Jacobs Levy Equity Management Inc. lifted its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 19.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 568,479 shares of the company’s stock after acquiring an additional 92,753 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in Ventyx Biosciences were worth $1,239,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Deerfield Management Company L.P. Series C boosted its holdings in Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after purchasing an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC boosted its position in Ventyx Biosciences by 153.2% in the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock worth $4,299,000 after purchasing an additional 1,193,024 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Ventyx Biosciences by 31.2% during the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after purchasing an additional 410,000 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Ventyx Biosciences during the 2nd quarter valued at about $608,000. Finally, LMR Partners LLP bought a new position in shares of Ventyx Biosciences in the 3rd quarter worth approximately $218,000. 97.88% of the stock is currently owned by institutional investors.

Insider Activity at Ventyx Biosciences

In other news, CEO Raju Mohan acquired 261,752 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was purchased at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the transaction, the chief executive officer now directly owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 18.18% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on VTYX shares. Wells Fargo & Company dropped their price target on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright restated a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th. Finally, Canaccord Genuity Group lowered their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Ventyx Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Ventyx Biosciences Price Performance

Ventyx Biosciences stock opened at $3.12 on Monday. Ventyx Biosciences, Inc. has a 1 year low of $1.67 and a 1 year high of $11.48. The firm’s 50 day moving average price is $2.23 and its 200-day moving average price is $2.51. The stock has a market cap of $220.62 million, a P/E ratio of -1.32 and a beta of 0.48.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.